Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry

Hee-Soon Park MD1 | Young-Hoon Kim MD, PhD1 | June Soo Kim MD, PhD2 | Yong-Seog Oh MD, PhD3 | Dong-Gu Shin MD, PhD4 | Hui-Nam Pak MD, PhD5 | Gyo-Seung Hwang MD, PhD6 | Kee-Joon Choi MD, PhD7 | Seil Oh MD, PhD8 | Jin-Bae Kim MD, PhD9 | Man-Young Lee MD, PhD10 | Hyung-Wook Park MD, PhD11 | Dae-Kyeong Kim MD, PhD12 | Eun-Sun Jin MD, PhD13 | Jae-Seok Park MD14 | Il-Young Oh MD, PhD15 | Dae-Hee Shin MD, PhD16 | Hyoung-Seob Park MD, PhD17 | Jun Hyung Kim MD, PhD18 | Nam-Ho Kim MD, PhD19 | Min-Soo Ahn MD, PhD20 | Bo-Jeong Seo MPH21 | Young-Joo Kim MS21 | Seongsik Kang MD, MBA22 | Juneyoung Lee PhD23

1Internal Medicine, Korea University College of Medicine, Seoul, Korea
2Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
4Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
5Internal Medicine, Severance Hospital, Yonsei University Health System, Seoul, Korea
6Internal Medicine, Ajou University Hospital, Suwon, Korea
7Internal Medicine, Asan Medical Center, Ulsan University, Seoul, Korea
8Internal Medicine, Seoul National University Hospital, Seoul, Korea
9Internal Medicine, Kyung Hee University Medical Center, Seoul, Korea
10Internal Medicine, Yeoju St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
11Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
12Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea
13Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea
14Internal Medicine, Sejong General Hospital, Bucheon, Korea
15Internal Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Korea
16Internal Medicine, Gangneung Asan Hospital, Gangneung, Korea
17Internal Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea
18Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea
19Internal Medicine, Wonkwang University Hospital, Iksan, Korea
20Internal Medicine, Yonsei University, Wonju Severance Christian Hospital, Wonju, Korea
21Outcomes Research/Real World Data, Corporate Affairs & Health and Value, Pfizer Pharmaceuticals Korea Ltd., Seoul, Korea
22Internal Medicine -Medical, Pfizer Pharmaceuticals Korea Ltd., Seoul, Korea
23Department of Biostatistics, College of Medicine, Korea University, Seoul, Korea

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2019 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
**INTRODUCTION**

Atrial fibrillation (AF) carries the highest risk of stroke and thromboembolism, and its prevalence increases with increasing life expectancy.\(^1\)\(^2\) Risk-based oral antithrombotic therapy is recommended for all patients with AF.\(^3\) In patients with nonvalvular AF, vitamin K antagonists (VKA) have traditionally been used as oral anticoagulants (OAC) but have recently been replaced by novel oral anticoagulants (NOAC).

Approximately 56% and 11% of AF patients have concomitant cardiovascular disease including ischemic heart disease and peripheral arterial disease, respectively.\(^4\)\(^5\) Current guidelines recommend that concomitant antiplatelet (APL) therapy and OAC therapy are indicated APL in patients with high embolic risk AF,\(^3\) but this combination therapy is known to increase one's bleeding risk.\(^6\)\(^7\) VKA has considerable limitations including its narrow therapeutic window and interaction with other drugs, which may increase the patient's bleeding risk. Several previous studies of the combined use of APL and VKA showed a reduced benefit for preventing thromboembolic or bleeding events compared with VKA monotherapy.\(^8\)\(^9\) However, data are lacking about the control status of VKA in patients who are taking VKA+APL compared to VKA monotherapy.

This study aimed to investigate the appropriate use of anticoagulation with VKA by evaluating the control status of INR and the discontinuation rate of VKA in patients taking VKA+APL compared with those taking VKA alone.

**METHODS**

2.1 Study design and study population

The Korean Atrial Fibrillation Investigation II was a multicenter noninterventional prospective study that enrolled 877 patients between April 2013 and March 2014 at 20 tertiary hospitals in the Republic of Korea. The patients who met all of the following criteria were included: 1) age ≥ 20 years; 2) NVAF diagnosis and a CHADS\(_2\) score ≥ 1; 3) newly started VKA (within the previous 3 months) for the prevention of stroke and thromboembolism; 4) available for regular INR monitoring and follow-up of 1 year; and 5) ability to understand the study protocol and willingness to complete the subject information sheet and informed consent form. This study was approved by the Institutional Review Boards of all participating institutions. All procedures have been performed in accordance with the hospital’s ethics standards and the 1964 Declaration of Helsinki. All patients provided informed consent prior to enrolling in the study.
2.2 | Data collection and follow-up

All variables were collected by medical chart reviews. All data were collected prospectively until the end of 1-year follow-up. Follow-up data after enrollment were obtained when the patients visited the hospitals regularly. Demographic features, clinical characteristics including risk factors of stroke or bleeding, and information about VKA treatments were collected at baseline. At follow-up, the VKA dose, INR levels, reasons for changing the VKA dose or changing from VKA to another drug, and concomitant APL type were investigated via medical chart reviews. In addition, whether there was a permanent discontinuation of VKA, the reasons for the discontinuation, and the type of drug changed were recorded.

2.3 | Treatment

VKA treatments including discontinuation, switching to NOAC, or adding APL were clinically decided at the physician’s discretion. Adding APL indicated aspirin 100 mg and/or clopidogrel 75 mg were administered.

2.4 | End points and definition

The primary end point was the achievement of the optimal INR range evaluated by the point prevalence of patients with the optimal INR range and proportion of tests within the optimal INR range (PTR), which was defined as well-controlled for ≥ 60% during the 12 months of therapy. The secondary end point was the persistence rate of VKA treatment, and the reason for discontinuing VKA or switching to other drugs was investigated. Clinically relevant bleeding was a composite of major and minor bleeding according to Thrombolysis in Myocardial Infarction criteria and bleeding requiring medical attention.

2.5 | Statistical analysis

Comparisons of patient’s characteristics between the groups were made by Student’s t test or the Mann-Whitney U test for numerical variables or the Chi-square test for categorical variables as appropriate. In multiple response items, the Chi-square test for an equality of proportions was used to identify the differences between the two groups.

During the follow-up from the baseline, INR values were collected to investigate the quality of VKA. The achievement of optimal INR range (INR 2.0–3.0) in patients prescribed VKA only or VKA+APL was evaluated by point prevalence of patients with optimal INR range and PTR, which was defined as well-controlled for ≥ 60%.

For bleeding events and discontinuation events of VKA use, 1-year event rates were calculated using Kaplan–Meier analysis. Among the two groups, differences in the event rates were analyzed using the log-rank test.

All statistical analyses were conducted with SAS software version 9.4 (SAS Institute, Cary, NC, USA), and a two-tailed P value < 0.05 was considered statistically significant.

### TABLE 1 Baseline features of the patients without a bleeding history

|                          | Total (N = 866) | VKA with APL (N = 229) | VKA without APL (N = 637) | P-value |
|--------------------------|----------------|------------------------|---------------------------|---------|
| Male, n (%)              | 522 (60.3)     | 133 (58.1)             | 389 (61.1)                | 0.43a   |
| Age, y                   | 67.7 ± 10.1    | 67.1 ± 10.1            | 67.9 ± 10.1               | 0.32b   |
| <65, n (%)               | 308 (25.6)     | 86 (37.6)              | 222 (34.9)                | 0.66c   |
| ≥75, n (%)               | 272 (31.4)     | 62 (27.1)              | 210 (33.0)                |         |
| BMI (kg/m²)              | 24.8 ± 3.2     | 25.2 ± 3.3             | 24.7 ± 3.2                | 0.07d   |
| AF duration (mo)         | 18.2 ± 34.0    | 22.3 ± 33.9            | 16.7 ± 34.0               | 0.014c   |
| Type of AF, n (%)        |                |                       |                           | <0.0001d |
| First diagnosed          | 93 (10.7)      | 29 (12.7)              | 64 (10.1)                 |         |
| Paroxysmal               | 267 (30.8)     | 70 (30.6)              | 197 (30.9)                |         |
| Persistent               | 343 (39.6)     | 66 (28.8)              | 277 (43.5)                |         |
| Long-standing persistent | 42 (4.9)       | 23 (10.0)              | 19 (3.0)                  |         |
| Permanent                | 82 (9.5)       | 27 (11.8)              | 55 (8.6)                  |         |
| Unknown                  | 39 (4.5)       | 14 (6.1)               | 25 (3.9)                  |         |

Abbreviations: AF, atrial fibrillation; APL, antiplatelet; BMI, body mass index; VKA, vitamin K antagonists.

aP value calculated by the chi-squared test.
bP value calculated by Student’s t test.
cP value calculated by the Mann-Whitney U test.
|                   | Total (N = 866) | VKA with APL (N = 229) | VKA without APL (N = 637) | P-value |
|-------------------|----------------|------------------------|----------------------------|---------|
| CHA₂DS₂-VASc score | 3.0 ± 1.4      | 3.04 ± 1.5             | 2.91 ± 1.34                | 0.22a   |
| 1                 | 136 (15.7)     | 42 (18.3)              | 94 (14.8)                  |         |
| 2                 | 218 (25.2)     | 42 (18.3)              | 176 (27.6)                 |         |
| 3                 | 226 (26.1)     | 58 (25.3)              | 168 (26.4)                 |         |
| 4                 | 170 (19.6)     | 53 (23.1)              | 117 (18.4)                 |         |
| 5                 | 79 (9.1)       | 22 (9.6)               | 57 (9.0)                   |         |
| 6                 | 33 (3.8)       | 10 (4.4)               | 23 (3.6)                   |         |
| 7                 | 2 (0.2)        | 1 (0.4)                | 1 (0.2)                    |         |
| 8                 | 2 (0.2)        | 1 (0.4)                | 1 (0.2)                    |         |

Factors of CHA₂DS₂-VASc score

| Factor                  | Yes (N = 298) | No (N = 568) | P-value |
|-------------------------|---------------|--------------|---------|
| History of CHF          | 151 (17.4)    | 44 (19.2)    | 0.41b   |
| Hypertension            | 677 (78.2)    | 175 (76.4)   | 0.45b   |
| Age 65-74               | 286 (33.0)    | 81 (35.4)    | 0.38b   |
| Age ≥ 75                | 272 (31.4)    | 62 (27.1)    | 0.10b   |
| Diabetes                | 227 (26.2)    | 61 (26.6)    | 0.86b   |
| Stroke                  | 142 (16.4)    | 50 (21.8)    | 0.010b  |
| Vascular disease        | 40 (4.6)      | 16 (7.0)     | 0.047b  |
| Female                  | 344 (39.7)    | 96 (41.9)    | 0.43b   |
| HAS-BLED score          | 1.5 ± 0.6     | 1.9 ± 0.7    | <0.0001a|
| 1                       | 434 (61.4)    | 64 (28.0)    | 0.0017b |
| 2                       | 224 (31.7)    | 123 (53.7)   | 0.21b   |
| 3                       | 47 (6.7)      | 41 (17.9)    | 0.0001b |
| 4                       | 2 (0.3)       | 1 (0.4)      |         |

Factors of HAS-BLED score

| Factor                  | Yes (N = 298) | No (N = 568) | P-value |
|-------------------------|---------------|--------------|---------|
| Hypertension            | 32 (3.7)      | 7 (3.1)      | 0.55b   |
| Abnormal renal          | 13 (1.5)      | 2 (0.9)      | 0.36b   |
| Abnormal liver          | 1 (0.1)       | 1 (0.4)      | 0.095b  |
| Stroke                  | 107 (12.4)    | 33 (14.4)    | 0.27b   |
| Bleeding                | 0 (0.00)      | 0 (0.0)      |         |
| Labile INRs             | 72 (8.3)      | 12 (5.2)     | 0.050b  |
| Elderly (Age > 65)      | 529 (61.1)    | 135 (59.0)   | 0.44b   |

Drug/Alcohol

| Drug/Alcohol | Yes (N = 298) | No (N = 568) | P-value |
|--------------|---------------|--------------|---------|
| Antiplatelet | 229 (26.4)    | 0 (0.0)      | <0.0001b|
| Aspirin      | 191 (83.4)    | 0 (0.0)      |         |
| Clopidogrel  | 17 (7.4)      | 0 (0.0)      |         |
| DAPT         | 18 (7.9)      | 0 (0.0)      |         |
| Other        | 3 (1.3)       | 0 (0.0)      |         |
| NSAIDs       | 0 (0.00)      | 0 (0.0)      |         |
| Alcohol history | 48 (5.5)    | 30 (4.7)     | 0.074b  |

Abbreviations: DAPT, dual anti platelet therapy; INR, international normalized ratio; NSAIDs, non-steroidal anti-inflammatory drugs.

aP value calculated by the Mann-Whitney U test.
bP value calculated by the chi-squared test for equal proportions between groups.
cMultiple response items.
3 | RESULTS

3.1 | Patients

Among the 877 NVAF patients in the KOREan Atrial Fibrillation Investigation (KORAF) II registry, 866 (98.7%) without a bleeding history were analyzed. The mean patient age was 67.7 ± 10.1 years; 60.3% of them were male. Patients were divided into the VKA+APL group (n = 229) and the VKA alone group (n = 637). The patients’ baseline characteristics are summarized in Table 1. There was no intergroup difference in age or sex. The proportion of patients with paroxysmal AF was similar between groups; however, there was a higher proportion of patients with nonparoxysmal AF in the VKA alone group than in the VKA+APL group. However, AF duration was longer in the VKA+APL group than in the VKA alone group (22.3 ± 33.9 vs 16.7 ± 34.0, respectively, P = 0.01).

3.2 | Thromboembolic risk and bleeding risk

The factors contributing to the CHA2DS2-VASc and HAS-BLED scores are shown in Table 2. There was no intergroup difference.
PARK et al.

in CHA₂DS₂-VASc score (3.0 ± 1.5 and 2.9 ± 1.3, \( P = 0.22 \) for the VKA+APL and VKA alone groups, respectively), while the distribution of factors was similar between the two groups except for stroke and vascular disease. More patients had a history of previous stroke and vascular disease in the VKA+APL group than in the VKA alone group (21.8% vs 14.4%, respectively, \( P = 0.01 \); 7.0% vs 3.8%, respectively, \( P = 0.047 \)). The HAS-BLED score was slightly higher in the VKA+APL group than in the VKA alone group (1.9 ± 0.7 vs 1.3 ± 0.5, respectively, \( P < 0.001 \)). All patients in the VKA+APL group were taking at least 1 APL, while 18 patients (7.9%) were on dual APL therapy (DAPT).

3.3 INR control

During follow-up, the mean INR level was lower in the VKA+APL group than in the VKA alone group (1.66 ± 0.8 vs 1.94 ± 0.94, respectively, \( P = 0.0005 \)); however, there was no intergroup difference in a PTR of 60% (33.9% vs 35.3%, respectively, \( P = 0.74 \)) (Table 3). Among all patients who took VKA long term, the number with a suboptimal INR level (INR < 2) decreased and the number within the optimal INR range increased. However, for 12 months of follow-up, >50% of patients were out of the optimal INR level range; the VKA alone and VKA+APL groups showed similar trends (Figure 1).

3.4 Discontinuation of VKA

Sixty-four (28.8%) patients in the VKA+APL group and 150 (24.2%) in the VKA alone group discontinued VKA. Fifteen (6.6%) patients in the VKA+APL group and 42 (6.6%) patients in the VKA alone group switched all medications to NOAC. A total of 29 (12.7%) patients in the VKA+APL group discontinued VKA and remained on APL only, while 69 (10.8%) patients in the VKA alone group started an APL agent other than VKA (Table 4). The most common reason for starting NOAC instead of the previous medication was uncontrolled INR level.

### TABLE 4 VKA discontinuation and switching type

| Switching Type                        | Total (N = 866) | VKA with APL (N = 229) | VKA without APL (N = 637) | \( P \)-value* |
|---------------------------------------|-----------------|------------------------|---------------------------|---------------|
| Discontinue VKA                       | 214 (25.4)      | 64 (28.8)              | 150 (24.2)                | 0.29          |
| Switch to NOAC                        | 57              | 15                     | 42                        |               |
| Switch to Aspirin                     | 58              | 19                     | 39                        |               |
| Switch to clopidogrel                 | 21              | 4                      | 17                        |               |
| Switch to DAPT                        | 15              | 5                      | 10                        |               |
| Switch to others                      | 4               | 1                      | 3                         |               |
| No switch                             | 59              | 20                     | 39                        |               |

Abbreviations: APL, antiplatelet; DAPT, dual anti platelet therapy; NOAC, novel oral anticoagulant; VKA, vitamin K antagonists.

*\( P \)-value calculated by the chi-squared test.

![Figure 2](image-url) Major cause of VKA discontinuation: (A) In patients treated with VKA and APL combination therapy; and (B) In patients treated with VKA alone therapy. VKA, vitamin K antagonist; APL, antiplatelet; Multiple responses were allowed; Unit was presented as response cases.
The major causes of VKA discontinuation were uncontrolled INR level, major bleeding, and clinically relevant nonmajor bleeding. (Figure 2). There was no intergroup difference in clinically relevant bleeding events (Figure 3). Among all patients except those who changed the therapy from VKA to NOAC during follow-up, those in the VKA+APL group more frequently discontinued VKA therapy than those in the VKA alone group (23.7% vs 18.7%, respectively, \( P = 0.047 \)) (Figure 4A). Including the patients who changed the therapy from VKA to NOAC, more patients discontinued VKA in VKA+APL group than in the VKA alone group (28.8% vs 24.2%, respectively, \( P = 0.045 \)) (Figure 4B).

**FIGURE 4** Discontinuation rate of VKA therapy: (A) In patients excluding those who changed the therapy from VKA to NOAC; and (B) In patients including those who changed the therapy from VKA to NOAC. VKA, vitamin K antagonists; NOAC, novel oral anticoagulant; APL, antiplatelet; CI, confidence interval; SE, standard error. *By Kaplan-Meier analysis; (a) log-rank test analysis.

The major findings of this study were that a lower proportion of individuals taking VKA achieved the optimal INR level with or without additional APL and that patients taking VKA+APL showed lower mean INR values than those taking VKA alone. More patients in the VKA+APL group discontinued VKA during the 1-year follow-up than in the VKA alone group. The main reasons for this were not only bleeding events but also physician concern about bleeding caused by unstable INR levels and interaction with other medications. Among the patients who discontinued the VKA, more than half of physicians in both groups abandoned the OAC therapy rather than switching to NOAC.

APL drugs prevent vascular endothelial hemostasis by dysregulating platelet aggregation, while VKA prevent thrombosis by inhibiting clotting protein formation. The different main targets of these drugs demonstrated that each medication is superior to the other in certain medical conditions: APL therapy reduces the frequency of ischemic events after percutaneous coronary intervention (PCI), while OAC therapy significantly reduces the incidence of
thromboembolism compared with APL therapy in AF patients. The current guidelines recommend OAC and APL combination therapy who are indicated APL therapy in individuals taking OAC due to the high embolic risk related to AF; however, because of the increased risk of bleeding with combination therapy, the efficacy of minimal use of APL in NVAF patients has been studied. In the general population, maintaining DAPT for a long-term duration decreased stent thrombosis and major adverse cardiovascular and cerebrovascular events in patients treated with drug-eluting stents (DES); however, the WOEST study showed that in patients taking OAC, single APL therapy had similar efficacy to and decreased bleeding events compared to DAPT. In cases of stable coronary artery disease, VKA+APL combination therapy increased risk of bleeding than VKA monotherapy without reduction in risk of recurrent coronary events or thromboembolism.

However, previous studies in practice showed that VKA+APL combination therapy did not reduce the risk of stroke more than VKA monotherapy. Without a history of coronary intervention, a Danish national cohort showed that VKA monotherapy was better able to prevent primary MI and stroke than aspirin (ASA) alone or VKA+ASA combination therapy; importantly, combination therapy was not associated with better prevention, and the bleeding risk increased. In a large Japanese cohort undergoing PCI, 8.3% of patients were diagnosed with AF, OAC therapy was underused, and its intensity was mostly suboptimal in patients maintaining DAPT; subsequently, OAC therapy was not associated with improved stroke prevention compared to no OAC therapy. A Korean single-center study demonstrated similar results among patients receiving DES implantation: 7.1% patients had a diagnosis of AF at the index PCI, only approximately 10% were treated with OAC+DAPT, and treatment was not associated with decreased ischemic events but was associated with increased bleeding risk compared to DAPT alone. There was a lack of information about INR value or control status of OAC in previous studies; in our analysis, a higher rate of discontinuation and suboptimal treatment of VKA in the VKA+APL group support the less favorable results of VKA+APL combination therapy than VKA monotherapy for preventing stroke events. Bleeding events and concerns caused by VKA instability made more physicians underuse or discontinue OAC therapy in the VKA+APL group than in the VKA alone group, a practice that can lead to inadequate stroke prevention in AF patients.

In the era of NOAC, a large randomized trial was performed to identify the optimal treatment strategy for patients who required simultaneous APL and OAC therapy. The PIONEER AF-PCI trial provided evidence that, in the acute stage of undergoing PCI, dose-adjusted factor Xa inhibitor+APL was associated with a lower bleeding rate and similar efficacy outcomes compared with VKA+APL in NVAF patients, but the efficacy benefit was uncertain. Clinical trials with another factor Xa inhibitor (apixaban and edoxaban) and direct thrombin inhibitor (dabigatran) to determine the safety and efficacy of NOAC in patients undergoing PCI are ongoing; these trials will provide further evidence of the role of NOAC for patients who require simultaneous OAC and APL use.

A previous retrospective study of a Korean cohort showed that only 42.4% of patients achieved an optimal INR level; in other words, more than half of the patients on VKA therapy are exposed to the potential risk of thromboembolic events. This prospective study showed similar results; specifically, no difference was seen in PTR ≥ 60% in the simultaneous VKA+APL use versus VKA alone groups. These results suggest that administration of APL does not effect to PTR status compared with no administration of APL; VKA therapy itself has a limitation in maintaining optimal OAC due to unstable PTR. NOAC is expected to improve the ability of OAC therapy to prevent thromboembolism by improving patient compliance and minimizing fluctuations in VKA concentrations. However, underuse of NOAC is another concern. In the real-world data of NOAC therapy, approximately 15% of patients were treated with a reduced dose despite having sufficient renal function. For optimal results to prevent thromboembolic events with OAC therapy, attention needs to be paid to avoid under-dosing in the absence of an obvious reason.

4.1 Study limitations

This study has several limitations. First, the relationship between INR level and rates of major adverse cardiac events was not studied. Second, indication of APL in VKA+APL group patients was not collected that baseline characteristics showed only factors of CHA2DS2-VAs score that do not include history of coronary artery disease except MI or type of stroke. Although the OAC and APL combination therapy increased the bleeding risk, it should have been prescribed to obviously indicated patients. Third, this study was a prospective observational study comparing between VKA+APL group and VKA only users, the underlying medical condition might be different. The confounding from differences in the demographic and clinical characteristics may exist.

5 CONCLUSIONS

The conditions of more than half of the patients treated with VKA in this cohort were under-controlled regardless of APL use or non-use. Patients in the VKA+APL group showed a lower mean INR level and a higher VKA discontinuation rate than those in the VKA alone group. Physicians discontinued the OAC therapy due to their concern about unstable INR levels or interactions with other medications. These findings suggest that other antithrombotic treatment options (i.e. NOAC or non-pharmacologic therapy) are warranted in NVAF patients. Further investigations of a standardized strategy for managing this double-edged treatment are needed for the optimal prevention of ischemic stroke and bleeding events in NVAF patients.

ACKNOWLEDGEMENTS

This research was sponsored by BMS/Pfizer Pharmaceuticals Korea Ltd. All authors have no other conflict of interest.
PARK ET AL.

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article.

ORCID

Hee-Soon Park https://orcid.org/0000-0003-0565-8066

REFERENCES

1. Chugh SS, Havmoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.
2. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
4. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
5. Proietti M, Raparelli V, Laroche C, Dan GA, Janion M, Popescu R, et al. Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace. 2017;19(9):1439–48.
6. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.
7. Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129(15):1577–85.
8. Lee CJ, Pallisgaard JL, Olesen JB, Carlson N, Lamberts M, Gislason GH, et al. Antithrombotic therapy and first myocardial infarction in patients with atrial fibrillation. J Am Coll Cardiol. 2017;69(24):2901–9.
9. Goto K, Nakai K, Shizuta S, Morimoto T, Shiomi H, Natsuaki M, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2014;114(1):70–8.
10. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281–91.
11. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66.
12. Choi HI, Ahn JM, Kang SH, Lee PH, Kang SJ, Lee SW, et al. Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents. JACC Cardiovasc Interv. 2017;10(11):1075–85.
13. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.
14. Shin HW, Kim YN, Bae HJ, Lee HM, Cho HO, Cho YK, et al. Trends in oral anticoagulation therapy among Korean patients with atrial fibrillation: the KOREan Atrial Fibrillation Investigation. Korean Circ J. 2012;42(2):113–17.
15. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–53.

How to cite this article: Park H-S, Kim Y-H, Kim JS, et al. Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry. J Arrhythmia. 2019;35:593–601. https://doi.org/10.1002/joa3.12183